April 28, 2023
Via: Biopharm InternationalAdaptive Biotechnologies Corporation announced on April 12, 2023 that it has begun a translational collaboration with Takeda. Adaptive Biotechnologies will use its clonoSEQ Assay to assess minimal residue disease (MRD) to start with the development and commercialization of Takeda’s pipeline […]
July 19, 2024
July 11, 2024
July 11, 2024